Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Smoking, Lung Neoplasms
Patient Function/Fitness and Psychosocial Health in Improving Health-Related Quality of Life in Patients With Stage I-IV Non-Small Cell Lung Cancer
This pilot trial studies patient function/fitness and psychosocial health in improving health-related quality of life and decreasing treatment-related toxicity in patients with stage I-IV non-small cell lung cancer.
- Trial name
- NCT02835066
- Testing
- Integrated Fitness Assessment, Psychosocial Assessment and Care, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Stage IIIA Non-small Cell Lung Cancer
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue in patients with…
- Trial name
- NCT01076231
- Testing
- proton beam radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
- Trial name
- ATLANTIC (NCT02087423)
- Testing
- MEDI4736
- Where
- 139 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- AstraZeneca
Lung Cancer, Malignant Mesothelioma
Alanosine in Treating Patients With Cancer
RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
- Trial name
- NCT00062283
- Testing
- L-alanosine
- Where
- 12 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer, Stage II-IIIA
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1013. The purpose of this neoadjuvant and adjuvant study is to evaluate the efficacy and safety of Serplulimab and…
- Conditions
- Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy, Neoadjuvant Therapy
- Trial name
- NCT05775796
- Testing
- Serplulimab and Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Lung Cancer
Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022646
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 22 sites in United States
- Volunteers
- 157 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
This randomized phase II trial studies how well pemetrexed disodium and carboplatin or cisplatin with or without erlotinib hydrochloride work in treating patients with epidermal growth factor receptor (EGFR) mutant positive stage…
- Trial name
- NCT01928160
- Testing
- pemetrexed disodium, carboplatin, cisplatin
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276588
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Cancer
Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00323362
- Testing
- gemcitabine hydrochloride, imatinib mesylate
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Rutgers, The State University of New Jersey
Carcinoma, Non-Small-Cell Lung
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
This study uses durvalumab (MEDI 4736), an experimental type of drug made by Astra Zeneca Pharmaceuticals, (limited partnership) LP, which in early studies has shown to possibly reduce the growth of certain types of lung cancer.
- Trial name
- NCT03148327
- Testing
- Durvalumab (MEDI 4736), Radiotherapy
- Where
- 4 sites in United States, Australia
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-small Cell Lung Carcinoma
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally…
- Trial name
- FORWARD (NCT04853342)
- Testing
- Drug: Furmonertinib 80 mg
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Lung Cancer
Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is more effective than no further treatment for non-small…
- Trial name
- NCT00002583
- Testing
- cisplatin, vinorelbine ditartrate
- Where
- 155 sites in United States, Canada
- Volunteers
- 482 people
- Sponsor
- NCIC Clinical Trials Group
Carcinoma, Non-Small-Cell Lung
Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA
Circulating tumor DNA (ctDNA) is a highly specific and effective biomarker for the detection of EGFR mutation status. We hypothesise AZD9291 is efficacious in patients with EGFR sensitizing mutations and T790M detected in plasma…
- Trial name
- PLASMA (NCT02811354)
- Testing
- AZD9291
- Where
- 8 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 108 people
- Sponsor
- National University Hospital, Singapore
Non-small Cell Lung Cancer
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC).
- Trial name
- NCT00097227
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- PAINT (NCT02073968)
- Testing
- Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Albert Einstein College of Medicine
Carcinoma, Non-Small-Cell Lung
Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
- Trial name
- NCT00061646
- Testing
- ABT-510/Thrombospondin-1 mimetic, Carboplatin/Taxol
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with chemotherapy prior to surgery, in patients with…
- Trial name
- NCT05132985
- Testing
- Icotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)
Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
This study aims to investigate the expression of Melanoma-associated antigen 3 (MAGE-A3), Melanoma-associated antigen C2 (MAGE-C2), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), L antigen family member 1 (LAGE-1)…
- Trial name
- NCT01837511
- Testing
- Data acquisition and analysis
- Where
- 3 sites in Singapore, South Korea
- Volunteers
- 377 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00334763
- Testing
- bevacizumab, carboplatin, chemoprotection
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Anemia, Drug/Agent Toxicity by Tissue/Organ
Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
- Trial name
- NCT00077311
- Testing
- darbepoetin alfa, pegfilgrastim, cisplatin
- Where
- 64 sites in United States
- Volunteers
- 160 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.